These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34176417)

  • 1. O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer's disease and related tauopathies: analysis of the patent literature.
    Bartolomé-Nebreda JM; Trabanco AA; Velter AI; Buijnsters P
    Expert Opin Ther Pat; 2021 Dec; 31(12):1117-1154. PubMed ID: 34176417
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice.
    Hastings NB; Wang X; Song L; Butts BD; Grotz D; Hargreaves R; Fred Hess J; Hong KK; Huang CR; Hyde L; Laverty M; Lee J; Levitan D; Lu SX; Maguire M; Mahadomrongkul V; McEachern EJ; Ouyang X; Rosahl TW; Selnick H; Stanton M; Terracina G; Vocadlo DJ; Wang G; Duffy JL; Parker EM; Zhang L
    Mol Neurodegener; 2017 May; 12(1):39. PubMed ID: 28521765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MK-8719, a Novel and Selective
    Wang X; Li W; Marcus J; Pearson M; Song L; Smith K; Terracina G; Lee J; Hong KK; Lu SX; Hyde L; Chen SC; Kinsley D; Melchor JP; Rubins DJ; Meng X; Hostetler E; Sur C; Zhang L; Schachter JB; Hess JF; Selnick HG; Vocadlo DJ; McEachern EJ; Uslaner JM; Duffy JL; Smith SM
    J Pharmacol Exp Ther; 2020 Aug; 374(2):252-263. PubMed ID: 32493725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.
    Yu Y; Zhang L; Li X; Run X; Liang Z; Li Y; Liu Y; Lee MH; Grundke-Iqbal I; Iqbal K; Vocadlo DJ; Liu F; Gong CX
    PLoS One; 2012; 7(4):e35277. PubMed ID: 22536363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based discovery and development of novel O-GlcNAcase inhibitors for the treatment of Alzheimer's disease.
    Li X; Han J; Bujaranipalli S; He J; Kim EY; Kim H; Im JH; Cho WJ
    Eur J Med Chem; 2022 Aug; 238():114444. PubMed ID: 35588599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thiamme2-G, a Novel O-GlcNAcase Inhibitor, Reduces Tau Hyperphosphorylation and Rescues Cognitive Impairment in Mice.
    Pan D; Gu JH; Zhang J; Hu Y; Liu F; Iqbal K; Cekic N; Vocadlo DJ; Dai CL; Gong CX
    J Alzheimers Dis; 2021; 81(1):273-286. PubMed ID: 33814439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The O-GlcNAc Modification of Recombinant Tau Protein and Characterization of the O-GlcNAc Pattern for Functional Study.
    El Hajjar L; Bridot C; Nguyen M; Cantrelle FX; Landrieu I; Smet-Nocca C
    Methods Mol Biol; 2024; 2754():237-269. PubMed ID: 38512671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies.
    Permanne B; Sand A; Ousson S; Nény M; Hantson J; Schubert R; Wiessner C; Quattropani A; Beher D
    ACS Chem Neurosci; 2022 Apr; 13(8):1296-1314. PubMed ID: 35357812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological Inhibition of O-GlcNAcase Enhances Autophagy in Brain through an mTOR-Independent Pathway.
    Zhu Y; Shan X; Safarpour F; Erro Go N; Li N; Shan A; Huang MC; Deen M; Holicek V; Ashmus R; Madden Z; Gorski S; Silverman MA; Vocadlo DJ
    ACS Chem Neurosci; 2018 Jun; 9(6):1366-1379. PubMed ID: 29460617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring of Intracellular Tau Aggregation Regulated by OGA/OGT Inhibitors.
    Lim S; Haque MM; Nam G; Ryoo N; Rhim H; Kim YK
    Int J Mol Sci; 2015 Aug; 16(9):20212-24. PubMed ID: 26343633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sugar Kick Prevents Memory Impairment.
    Rudrawar S; Ryan P
    J Med Chem; 2019 Nov; 62(22):10059-10061. PubMed ID: 31668062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diaminocyclopentane-derived
    Weber P; Mészáros Z; Jagečić D; Hribljan V; Mitrečić D; Bojarová P; Slámová K; Vrba J; Kulik N; Křen V; Stütz AE
    Chem Commun (Camb); 2022 Aug; 58(63):8838-8841. PubMed ID: 35849011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo.
    Yuzwa SA; Macauley MS; Heinonen JE; Shan X; Dennis RJ; He Y; Whitworth GE; Stubbs KA; McEachern EJ; Davies GJ; Vocadlo DJ
    Nat Chem Biol; 2008 Aug; 4(8):483-90. PubMed ID: 18587388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diazaspirononane Nonsaccharide Inhibitors of O-GlcNAcase (OGA) for the Treatment of Neurodegenerative Disorders.
    Martínez-Viturro CM; Trabanco AA; Royes J; Fernández E; Tresadern G; Vega JA; Del Cerro A; Delgado F; García Molina A; Tovar F; Shaffer P; Ebneth A; Bretteville A; Mertens L; Somers M; Alonso JM; Bartolomé-Nebreda JM
    J Med Chem; 2020 Nov; 63(22):14017-14044. PubMed ID: 33197187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Dysregulation of OGT/OGA Cycle Mediates Tau and APP Neuropathology in Down Syndrome.
    Zuliani I; Lanzillotta C; Tramutola A; Francioso A; Pagnotta S; Barone E; Perluigi M; Di Domenico F
    Neurotherapeutics; 2021 Jan; 18(1):340-363. PubMed ID: 33258073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy.
    Graham DL; Gray AJ; Joyce JA; Yu D; O'Moore J; Carlson GA; Shearman MS; Dellovade TL; Hering H
    Neuropharmacology; 2014 Apr; 79():307-13. PubMed ID: 24326295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased O-GlcNAc levels correlate with decreased O-GlcNAcase levels in Alzheimer disease brain.
    Förster S; Welleford AS; Triplett JC; Sultana R; Schmitz B; Butterfield DA
    Biochim Biophys Acta; 2014 Sep; 1842(9):1333-9. PubMed ID: 24859566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SIRT1 deficiency increases O-GlcNAcylation of tau, mediating synaptic tauopathy.
    Yin X; Li Y; Fan X; Huang F; Qiu Y; Zhao C; Zhou Z; Gu Q; Xia L; Bao J; Wang X; Liu F; Qian W
    Mol Psychiatry; 2022 Oct; 27(10):4323-4334. PubMed ID: 35879403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IP-LC-MSMS Enables Identification of Three Tau
    Bijttebier S; Rodrigues Martins D; Mertens L; Grauwen K; Bruinzeel W; Willems R; Bartolomé-Nebreda JM; Theunis C; Bretteville A; Ebneth A; Dillen L
    J Proteome Res; 2023 Apr; 22(4):1309-1321. PubMed ID: 36888912
    [No Abstract]   [Full Text] [Related]  

  • 20. Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.
    Šimić G; Babić Leko M; Wray S; Harrington C; Delalle I; Jovanov-Milošević N; Bažadona D; Buée L; de Silva R; Di Giovanni G; Wischik C; Hof PR
    Biomolecules; 2016 Jan; 6(1):6. PubMed ID: 26751493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.